Germantown, MD, United States of America

Jing-Hui Tian

This inventor holds 23 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Vaccine Formulations. Top assignees: Novavax, Inc., Valneva Austria Gmbh, Valneva USA, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jing-Hui Tian. Retrieved from https://idiyas.com/inventor/jing-hui-tian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 4 (Patent Applications = 13)

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 90(Granted Patents)

Location History:

Gaithersburg, MD (US) (2019)
Germantown, MD (US) (2017 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

Areas of Expertise:

Vaccine Compositions

Immunogenicity

Respiratory Disease

Multivalent Vaccines

Polypeptide

Influenza

Coronavirus

Toxin Proteins

Stability

Immune Responses

Nanoparticle Vaccines

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12714744 - Coronavirus and influenza compositions and methods for using them (2026-08-25),

2. 12691171 - CORONAVIRUS VACCINE FORMULATIONS (2026-07-28),

3. 12491241 - CORONAVIRUS VACCINE FORMULATIONS (2025-12-09),

4. 12472246 - CORONAVIRUS VACCINE FORMULATIONS (2025-11-18),

5. 12324831 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2025-06-10),

6. 12257297 - Vaccine compositions having improved stability and immunogenicity (2025-03-25),

7. 12083228 - Methods and compositions for treating respiratory disease (2024-09-10),

8. 11938179 - Methods and compositions for inducing immune responses against (2024-03-26),

9. 11896664 - Corona virus vaccine formulations (2024-02-13),

10. 11896662 - Multivalent influenza nanoparticle vaccines (2024-02-13),

11. 11541112 - Coronavirus vaccine formulations (2023-01-03),

12. 11478540 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2022-10-25),

13. 11364294 - Vaccine compositions having improved stability and immunogenicity (2022-06-21),

14. 11357844 - Isolated polypeptide of the toxin A and toxin B proteins ofand uses thereof (2022-06-14),

15. 11278612 - Multivalent influenza nanoparticle vaccines (2022-03-22),

Title: Innovations by Jing-Hui Tian: A Leader in Biotechnology Patents

Introduction

Jing-Hui Tian, based in Germantown, MD, has made significant contributions to the field of biotechnology, holding an impressive 19 patents. His innovative work primarily focuses on the development of therapeutic agents and vaccines that play a crucial role in combating various diseases.

Latest Patents

Two of his most recent patents exemplify his groundbreaking work in the field. The first patent involves the isolated polypeptide of the toxin A and toxin B proteins along with their applications. This invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides, which contain the receptor binding domains of toxins A and B, as outlined in specific amino acid sequences. These polypeptides are designed to neutralize the toxic effects associated with these harmful proteins.

The second patent concerns vaccine compositions that exhibit improved stability and immunogenicity. This innovation involves nanoparticles that can be utilized in vaccines, where antigens from pathogens are surrounded by and associated with a detergent core. This formulation results in enhanced stability and immune response, making it a significant advancement in vaccine development, complete with details on dosages, formulations, and preparation methods.

Career Highlights

Throughout his career, Jing-Hui Tian has worked with prominent organizations, including Novavax, Inc. and Valneva Austria GmbH. His experience in leading biotechnology companies has significantly contributed to his expertise in vaccine research and development.

Collaborations

In addition to his work in these organizations, Tian has collaborated with esteemed colleagues such as Gale Smith and Gregory M. Glenn. These partnerships have fostered innovation and enhanced research outcomes, driving advancements in biomedical sciences.

Conclusion

Jing-Hui Tian’s extensive portfolio of patents and collaborations underscores his influential role in the biotechnological landscape. His contributions not only advance scientific knowledge but also pave the way for innovative solutions in healthcare. As he continues to develop cutting-edge technologies, the implications of his work will undoubtedly resonate throughout the biotech industry and beyond.

Profile summary based on public USPTO records.